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Abstract
Multiple sclerosis (MS), characterized by chronic inflammation, demyelination, and axonal damage, is a complicated
neurological disease of the human central nervous system. Recent interest in adipose stromal/stem cell (ASCs) for the
treatment of CNS diseases has promoted further investigation in order to identify the most suitable ASCs. To investigate
whether MS affects the biologic properties of ASCs and whether autologous ASCs from MS-affected sources could serve as
an effective source for stem cell therapy, cells were isolated from subcutaneous inguinal fat pads of mice with established
experimental autoimmune encephalomyelitis (EAE), a murine model of MS. ASCs from EAE mice and their syngeneic wild-
type mice were cultured, expanded, and characterized for their cell morphology, surface antigen expression, osteogenic and
adipogenic differentiation, colony forming units, and inflammatory cytokine and chemokine levels in vitro. Furthermore, the
therapeutic efficacy of the cells was assessed in vivo by transplantation into EAE mice. The results indicated that the ASCs
from EAE mice displayed a normal phenotype, typical MSC surface antigen expression, and in vitro osteogenic and
adipogenic differentiation capacity, while their osteogenic differentiation capacity was reduced in comparison with their
unafflicted control mice. The ASCs from EAE mice also demonstrated increased expression of pro-inflammatory cytokines
and chemokines, specifically an elevation in the expression of monocyte chemoattractant protein-1 and keratin
chemoattractant. In vivo, infusion of wild type ASCs significantly ameliorate the disease course, autoimmune mediated
demyelination and cell infiltration through the regulation of the inflammatory responses, however, mice treated with
autologous ASCs showed no therapeutic improvement on the disease progression.
Citation: Zhang X, Bowles AC, Semon JA, Scruggs BA, Zhang S, et al. (2014) Transplantation of Autologous Adipose Stem Cells Lacks Therapeutic Efficacy in the
Experimental Autoimmune Encephalomyelitis Model. PLoS ONE 9(1): e85007. doi:10.1371/journal.pone.0085007
Editor: Ralf Andreas Linker, Friedrich-Alexander University Erlangen, Germany
Received April 13, 2013; Accepted November 27, 2013; Published January 21, 2014
Copyright:  2014 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding for this study was provided by Tulane University and the Pennington Biomedical Research Foundation. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: bbunnell@tulane.edu
Introduction
Multiple sclerosis (MS), characterized by chronic inflammation,
demyelination, and axonal damage, is a complicated neurological
disease of human central nervous system (CNS) and is the most
common neurological disease in young adults among 20–40 years
old [1–3]. So far, immunotherapies are the most commonly used
treatment approaches for MS, ranging from nonselective immu-
nosuppressor, such as interferon-b or glatiramer acetate, to highly
specific immune interventions such as the monoclonal antibody
natalizumab against the cell adhesion molecule a4-integrin [2,3].
Although the existing treatments for MS partially alleviate
symptoms, they do not halt the ongoing progression of neurode-
generation. Experimental autoimmune encephalomyelitis (EAE),
which exhibits many clinical and histological features of MS, is the
most widely used and best characterized experimental animal
model for MS. EAE is usually induced by immunization with
myelin proteins such as myelin oligodendrocyte glycoprotein
(MOG) and adjuvants, which results in the immune system
mediated destruction of the myelinated CNS [4,5].
Bone marrow-derived mesenchymal stem cell (BM-MSC) based
cell therapy for EAE have been extensively studied [6–12] because
of the BM-MSCs’ self-renewal ability, potential of differentiation
into multiple lineages, and immunomodulatory effects through the
secretion of cytokines and chemokines. Although bone marrow
remains the main source for mesenchymal stem cells in clinical
trials, adipose tissue is an ideal source due to its abundance, easy
accessibility, and the feasibility of harvesting by a minimally
invasive procedure. Moreover, large amounts of cells can be
isolated from the adipose tissue, yielding 100–500 fold higher stem
cells per tissue volume than bone marrow [13,14]. Meanwhile,
adipose-derived stromal/stem cells (ASCs) have similar self-
renewal abilities, surface epitopes, growth kinetics, and cytokine
expression profiles as their counterparts from bone marrow [15–
20].
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Studies have been performed using ASC or genetically-modified
ASC therapy for the treatment of EAE [14,21]. The results from
these studies clearly demonstrated that ASC-based cell therapy
could ameliorate the disease and enhance anti-inflammatory
responses. Consequently, it is important to consider the question of
whether the outcome of ASCs infusion differs when cells are
sourced from EAE afflicted or unaffected controls. It is presumed
that autologous ASC transplantation will have lower rates of post-
transplant complications and lower risk of transmission of
infectious diseases compared to allogeneic transplantation. More-
over, although allogeneic MSC therapy has been used for the
treatment of various diseases, such as Graft versus host disease,
some studies have shown that allogeneic MSCs transplantation
could be rejected by the host immune system [22]. In contrast,
autologous transplantation of stem cells does not have issues
related to donor availability or risk of histo-incompatibility. Thus,
autologous ASCs offer numerous theoretical advantages from
regulatory, histocompatibility, and immunological perspectives
[23].
In the in vitro studies presented here, ASCs were isolated from
diseased EAE mice, cultured, expanded, and characterized by
means of flow cytometry, differentiation assays, colony forming
unit assays, and real-time PCR to determine whether the EAE
alters ASCs properties relative to those derived from unafflicted
control mice. In vivo, ASCs from the EAE mice, transplanted back
in the EAE mouse model, were assessed for their therapeutic
effects on delaying the disease course, ameliorating the demyelin-
ation and modulation of the immune responses.
Materials and Methods
EAE induction and treatment
All the protocols and experimental procedures were approved
by the Institutional Animal Care and Use Committee at Tulane
University. Female C57Bl/6 mice, 6 to 8 weeks old, were
purchased from Charles River Laboratories (Wilmington, MA),
and allowed 7 days to acclimate before the start of the study.
Chronic EAE was induced in the female C57Bl/6 mice by
subcutaneous immunization with MOG35–55 (Anaspec, San
Diego, CA), which was emulsified in Complete Freund’s adjuvant
with 8 mg/ml of Mycobacterium tuberculosis H35RA (Difco,
Detroit, MI) in 1:1 ratio, and 100 ml (100 ng) of emulsified
MOG35–55 was injected sub-cutaneously at each side of the base of
the tail respectively. Each mouse also received 100 ml (200 ng) of
pertussis toxin (List Biological Laboratories, Campbell, CA) by
intraperitoneal (i.p.) injection, and the injection of toxin was
repeated 2 days later. Concurrently, a total of 16106 ASCs from
the EAE mice (EAEASC) or from unafflicted control mice
(WtASC) suspended in 100 ml total volume of HBSS were injected
into the mice intraperitoneally. Negative control animals consisted
of EAE-induced mice injected with equal volumes of vehicles only
(HBSS), and positive control animals were non-EAE-induced
normal mice which only received one i.p. injection of the equal
volume of HBSS. The experiments were conducted on three
independent cohorts with 20 mice total for each treatment and
control group.
Isolation and culture of adipose-derived stem cells
The subcutaneous inguinal fat pads were isolated from the
Hank’s balanced salt solution (HBSS) (Life Technologies, Grand
Island, NY)-treated EAE mice and HBSS treated normal non-
induced mice on post EAE disease induction (PDI) day 30, rinsed
with HBSS to remove blood and hair contamination, and digested
with 0.1% collagenase type 1 solution (Life Technologies) for
approximately 4 hours at 37uC under mild agitation. The digested
adipose tissues were then filtered through a 70-mm nylon mesh cell
strainer (BD Biosciences, Bedford, MA), and centrifuged at 5006g
for 10 minutes at room temperature (RT). The pellets were re-
suspended and cultured in the cell culture medium (CCM), made
of DMEM:F12 (Life Technologies) supplemented with 10% fetal
bovine serum(FBS, Atlanta Biologicals, Atlanta, GA), 2 mM L-
glutamine (Life Technologies), and 1% antibiotic/antimycotic
(Penicillin/streptomycin/amphotericin, Life Technologies). After
24 hours, the non-adherent cells were washed with phosphate
buffered saline (PBS, Life Technologies) and fresh CCM were
added. When cells reached 70–80% confluence, the passage 0 cells
were lifted with 0.25% trypsin/1 mM EDTA (Life Technologies)
and sub-cultured at 100 cells/cm2 in CCM on 145 cm2 tissue
culture dishes (Nalge Nunc International, Rochester, NY). Media
was replaced every 3–4 days, and cells were routinely passaged
when they reached 70% confluence unless otherwise noted. For all
experiments, ASC lines between passages 3–5 were used.
Flow cytometry
The following antibodies were used to check the cell surface
marker profiles of EAEASCs and WtASCs: CD29, CD34, CD31,
CD45, CD11b, and Sca1 (stem cell antigen-1). All of the
antibodies were purchased from BD Biosciences. The ASCs were
cultured, trypsinized, pelleted, and re-suspended in 500 ml PBS.
The cells were incubated with the antibodies for 30 minutes at
RT, then washed with PBS, and analyzed by Cytomics FC500
(Beckman Coulter, Brea, CA). The results were analyzed with
CXP analysis software (Beckman Coulter).
Differentiation
ASCs at passage 5 were cultured on 6-well Nunc plates (Nalge
Nunc International) to approximately 90% confluence before
adipogenic and osteogenic differentiation media were added.
Adipogenic differentiation medium was made with CCM supple-
mented with 5 mg/ml insulin, 50 mM indomethacin, 1 mM
dexamethasone and 0.5 mM 3-isobutyl-1-methylxanthine (all
media supplements were purchased from Sigma, St Louis, MO).
Osteogenic differentiation medium was made with CCM supple-
mented with 1 nM dexamethasone, 20 mM b-glycerolphosphate,
50 mM L-ascorbic acid 2-phosphate sesquimagnesium salt, and
50 ng/ml L-thyroxine sodium pentahydrate. Media were changed
twice per week for 3 weeks. For adipogenic differentiation, the cells
were washed with PBS, fixed with 10% formalin (Sigma) for
20 minutes at RT, washed again with PBS, stained with Oil Red-
O (Sigma) for 20 minutes at RT, and washed with PBS until wash
was clear. For the detection of osteogenesis, the cells were washed
with PBS, fixed with 10% formalin for 20 minutes at RT, washed
with deionized (DI) water, stained with Alizarin Red (Sigma) for
20 minutes at RT, and washed with DI water until wash was clear.
Images were acquired at 106 for adipogenic differentiation and
46 for osteogenic differentiation on Nikon Eclipse TE200
(Melville, NY) with Nikon Digital Camera DXM1200F using the
Nikon ACT-1 software version 2.7.
The levels of adipogenic and osteogenic differentiation were also
quantified. For the quantification of adipogenic differentiation, the
accumulated lipids were eluted with isopropanol after images were
captured. The amount of Oil Red O was measured by recording
the optical density (OD) of the solution at 584 nm. The results
were normalized to the protein content of the samples with the
BCA assay (Thermo Scientific, Rockford, IL). For the quantitative
osteogenesis assay, the cells were de-stained, after images were
taken, with 10% cetylpyridinium chloride (Sigma) for 30 minutes
at RT. The amount of Alizarin Red was determined by measuring
Autologous ASCs for the Treatment of EAE
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the OD of the solution at 584 nm. The results were normalized to
the protein content of the samples.
Colony forming unit assay
ASCs at passage 5 were seeded onto 56.7 cm2 Nunc cell culture
plates (Nalge Nunc International) in 5 replicates at a total of 100
cells per plate. Growth media was changed every 3–4 days. After
14 days, the cells were washed with PBS, stained with 3% crystal
violet in 100% methanol for 30 minutes at RT, and then washed
with DI water at least 3 times to remove excess dye. All colonies
greater than 2 mm in diameter were counted. The cells were de-
stained with methanol, after images were taken, for 40 minutes
under mild agitation at RT. The amount of staining was measured
by recording the optical density (OD) of the solution at 584 nm,
and the arbitrary unit was defined as the OD divided by the pre-
counted colony number.
Real-time quantitative PCR
Cells at passage 5 were seeded onto 145 cm2 tissue culture
dishes with a density of 16106 cells/dish, and incubated for
24 hours. The cells were then trypsinized and pelleted for
extraction total cellular RNA using RNeasy Mini Kit (Qiagen,
Valencia, CA). The concentration and purity of the RNA were
assessed by Nanodrop 2000 spectrophotometer (Thermo Scientif-
ic). RNA was first treated with DNase (Life Technologies), and first
strand cDNA syntheses were performed using iScript cDNA
Synthesis kit (Biorad, Hercules, CA). Real-time PCR was
performed to analyze the mRNA levels for mouse cytokines and
chemokines, specifically TNFa, IL-6, MCP-1, MIP-1a, RANTES,
KC, MIP-2a and VEGF. PCR reactions were performed using
CFX96 Real Time System (Biorad) in a total volume of 20 ml
containing 10 ml Taqman mastermix (Applied Biosystems, Foster
City, CA), 1 ml primer and probe mix (Applied Biosystems), 7 ml
dH2O and 2 ml template. Reaction mixtures were incubated at
50uC for 2 minutes and 95uC for 10 minutes, and reactions were
allowed to proceed via 40 cycles of melting at 95uC for 15 seconds,
annealing and extension at 60uC for 1 minute. The housekeeping
gene b-actin (UniGene: Mm328431) was used as internal
reference. Quantification was calculated using DDCt method [24].
Clinical Scoring
Mice were monitored daily for clinical signs of EAE by three
independent investigators. Clinical scores were based on a scale of
0–5 with a score of 0 indicating no disease; 1-limp tail (loss of tail
tone); 2-limp tail and hind limb weakness; 3-limp tail and partial
hind limb paralysis; 4-limp tail and complete hind limb paralysis;
and 5- moribund or dead.
Tissue Processing and Histological Analysis
On PDI day 30, animals were euthanized by exposure to CO2
and perfused with sterile PBS. Spinal cords were removed, fixed in
10% formalin (Thermo Scientific) and then embedded in paraffin.
Sections were cut at 5 microns on a microtome and stained for
Luxol Fast Blue/Crystal Violet (LFB, IHC World, Ellicott City,
MD) and Hematoxylin and Eosin (H&E) for identification of intact
myelin and infiltrating cells respectively. Histological images were
collected on an ImageScope (Aperio, Vista, CA), and the LFB
images were analyzed with Aperio Software. The quantification of
the percentage of positivity was determined by the percentage of
positive pixels divided by the total number of pixels in a given
section. The H&E images were analyzed with Fiji/Image J
software to quantify the number of total cells (i.e., cells $5 mm2)
per field at 406magnification [25]. Quantification was performed
on three sections per animal and three animals per group. Indices
were normalized to the average value obtained in normal un-
induced mice (set as 1).
Analysis of Spinal Cord Lesions
Spinal cord sections were prepared 5 microns thick and stained
with LFB and H&E for myelination and infiltrating cell detection,
respectively. Each section was analyzed using Aperio ImageScope
for quantitative measures of lesions. Lesion detection was
determined by dense areas of both LFB and H&E stain containing
high concentrations of infiltrating cells located in the ventral and
lateral columns of the spinal cord. Lesions were manually
Figure 1. Cell surface marker profiles of EAEASCs andWtASCs. A) Cells were analyzed by flow cytometry for MSC surface markers CD29, Sca1;
hematopoietic markers CD34 and CD45; phagocytic lineage marker CD11b; and endothelial marker CD31. Gray filled: isotype control; gray line:
WtASCs; black line: EAEASCs. B) Cell size based on forward scatter signal of flow cytometry (P = 0.26, t-test, n = 7).
doi:10.1371/journal.pone.0085007.g001
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delineated in H&E stained sections and subsequently analyzed
using modified positive pixel count algorithms specific for H&E
stained sections.
Lesions were scored according to categories established in Niimi
et al., 2013 [26]. Briefly, Grade 1- leptomeningeal cell infiltration,
Grade 2- mild perivascular cuffing, Grade 3- moderate perivas-
cular cuffing, Grade 4 – extensive perivascular cuffing.
Immunohistochemistry
Tissue sections (paraffin-embedded) were warmed on a heating
platform at 57uC for 30 minutes prior to deparaffinization. For
deparaffinization, all slides were submerged in HistoChoice
(Amresco, Solon, OH) twice for 5 min, 100% ethanol twice for
2 min, 95% ethanol twice for 2 min, 70% ethanol for 2 min, 50%
ethanol for 2 min, and DI water twice for 2 min. The
deparaffinized slides were submerged in citrate buffer pH 6.0
(10 mM) and heated for 30 min in a steamer. After cooling, the
slides were washed for 5 min in 16PBS and subsequently washed
with PBS-FSG-Tx-100 (10% v/v 106 PBS, 0.2% v/v fish skin
gelatin, and 0.1% v/v Triton x-100) for 5 min before incubation
for 1 h in a humidified chamber at RT with blocking solution,
which consisted of 10% normal goat serum (NGS) in PBS-FSG
(10% v/v 106PBS and 0.2% v/v fish skin gelatin). The primary
antibody to astrocytes (GFAP; 1:200, Sigma: C9205 Ms IgG1),
CD3 (1:200, Abcam, Cambridge, MA), CD11b (1:200, eBios-
ciences, San Diego, CA), CD45 (1:200, Invitrogen, Grand Island,
NY) was diluted in 10% NGS solution and applied to appropriate
experimental sections for overnight incubation in a humidified
chamber at 4uC. Control slides were treated with secondary
antibody-only (2u only). Following incubation, the slides were
washed in PBS-FSG-Tx-100 and PBS-FSG, each for 10 min. The
sections stained with anti-GFAP were then incubated in a
humidified chamber at RT for 1 hour with the secondary
antibody (e.g., anti-rat, with Alexa 594) in 10% NGS solution.
Slides were then washed twice in PBS-FSG-Tx-100 and once in
PBS-FSG. The slides were mounted with mounting medium with
DAPI (Vector Laboratories, INC. Burlingame, CA), and imaged
using a deconvolution microscope. Slides, stained with anti-CD3,
CD11b, and CD45, were incubated with HRP-conjugated
secondary antibodies (Abcam, Cambridge, MA) for 1 hour at
room temperature then processed with DAB peroxidase substrate
kit (Vector Laboratories, Inc., Burlingame, CA) followed by
Hematoxylin (Invitrogen, Grand Island, NY) counterstain. Slides
were washed, dehydrated, and mounted with Permount (Fish-
erChemicals, Fair Lawn, NJ).
Spinal cord sections analyzed with ImageScope were used to
identify CD3, CD11b, and CD45-positive cells within the
manually delineated lesions for each group. Using the positive
pixel count algorithm, the frequency of each antigen-specific cell
infiltrating within each lesion was determined by the number of
strong positive pixels (Nsp) divided by the total number of pixels
(NTotal) multiplied by 100.
Serum ELISA assay
On PDI day 30, blood samples were collected from each
treatment and control group to analyze circulating levels of
cytokines TNFa, IL-12 and IL-17 by ELISA assay (Invitrogen,
Grand Island, NY) according to the manufacturer’s instructions.
The concentration of each cytokine was calculated based on the
standard curve generated.
Statistical analysis
Data sets were analyzed by the Kruskal-Wallis non-parametric
one-way analysis of variance (ANOVA), followed by post-hoc
Dunnet multiple comparison tests versus the respective control
group. For pair-wise comparisons, the F-test was used to
determine whether a given pair of population variances was equal
(a,0.05). This information was then used in designating the
appropriate t-tests (typically heteroscedastic) to perform for
comparing the means of population pair, with significance defined
as P,0.05. All values were reported as mean 6 SD except for the
clinical scoring where the values were reported as means 6 SEM.
Results
Flow cytometric analysis of EAEASC
The cell morphology of EAEASCs was consistent with that of
the ASCs from the unafflicted control mice, which were fibroblast-
like in appearance (data not shown). EAEASCs and WtASCs were
analyzed by flow cytometry, and their cell surface antigens were
similar (Fig. 1A). Both cell types were positive for CD29 and ScaI,
while they were negative for endothelial (CD31), hematopoietic
markers (CD45 and CD34) and macrophage marker CD11b. The
sizes of both cell types were also analyzed based on the forward
Figure 2. Analysis of differentiation of EAEASCs and WtASCs
along osteogenic and adipogenic lineages. A) Differentiated
EAEASCs and WtASCs. Cells were incubated in adipogenic or osteogenic
differentiation media for 21days and stained, respectively, with Oil Red
O and Alizarin Red. For osteogenic differentiation, images were
collected at 46 magnification. For adipogenic differentiation, images
were obtained at 106magnification. B) Quantification of osteogenesis
and adipogenesis. For the quantitation of osteogenesis, the cells were
de-stained with 10% cetylpyridinium chloride after stained with Alizarin
Red. For the quantitation of adipogenesis, the cells were de-stained
with isopropanol. Optical density (OD) was measured at 584 nm and
normalized to protein content. The bar graph represents the ratio of
normalized OD of differentiated cells and normalized OD of control
cells. # means P,0.05 vs WtASCs (t-test, n = 3).
doi:10.1371/journal.pone.0085007.g002
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scatter signals of flow cytometry. As shown in Figure 1B, the cell
size of EAEASCs versus WtASCs was not significantly different (t-
test, P.0.05).
Differentiation assays for EAEASC
EAEASCs and WtASCs were cultured in osteogenic and
adipogenic differentiation medium for 3 weeks to test their lineage
differentiation efficiency. On day 21, the ASCs were stained with
Alizarin Red to assess bone mineralization, and with fresh Oil Red
O for lipid droplets. Both EAEASCs and WtASCs efficiently
differentiated into osteocytes and adipocytes (Fig. 2). However, as
shown in Figure 2A, the EAEASCs had reduced osteogenic
differentiation capacity when compared to the WtASCs. Quan-
tification of the differentiation levels of both cell types (Fig. 2B)
further demonstrated that WtASCs (OD ratio = 15.3962.88)
could differentiate into osteocytes to a much greater degree than
EAEASCs (OD ratio = 2.0360.35) (t-test, P,0.05) over the period
of the assay. Quantification of adipocyte differentiation indicated
that EAEASCs (OD ratio = 0.9060.11) had a similar differenti-
ation capacity as WtASCs (OD ratio = 0.8060.14) (t-test, P.0.05).
The graph in Figure 2B represents the ratios of OD of
differentiated cells normalized to control cells. Real-time PCR
analysis of osteogenic markers alkaline phosphatase and runt-
related transcription factor 2 in differentiated EAEASCs and
WtASCs showed that there was no difference in these two
transcriptional factors between the two cell types (data not shown).
Colony forming unit assay
EAEASCs and WtASCs were assessed for their self-renewal
ability by the colony forming unit (CFU) assay. All colonies greater
than 2 mm in diameter were counted. The results indicate that
EAEASCs (27.8611.12 CFU) have the same self-renewal capacity
as WtASCs (35.268.20 CFU) (Fig. 3A) (t-test, P.0.05). However,
the colony diameter or area of WtASC was much larger and the
intensity of the crystal violet stain was more intense when
compared to EAEASCs (Fig. 3B). Elution of the stain with
methanol, and determination of the optical density (OD) of the
solution at 584 nm were performed to quantitate these differences.
An arbitrary unit was defined as the OD divided by the pre-
counted colony numbers. As shown in Figure 3C, WtASCs
presented a much higher arbitrary CFU (4.5160.73%) than
EAEASCs (2.0960.43%) (t-test, P,0.05).
Figure 3. Colony forming unit assays for EAEASCs and WtASCs. A total of 100 cells were plated on 56.7 cm2 Nunc cell culture plates and
incubated for 14 days. Cells were stained with 3% crystal violet, and colonies 2 mm or larger in diameter were counted. # means P,0.05 vs WtASCs
(t-test, n = 5).
doi:10.1371/journal.pone.0085007.g003
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Figure 4. Real-time PCR analysis of cytokine and chemokine profiles of EAEASCs and WtASCs. Both cell types were cultured overnight,
trypsinized, and analyzed by real-time PCR to determine the expression levels of various cytokines and chemokines TNFa, IL-6, MCP-1, MIP-1a,
RANTES, KC, MIP-2a and VEGF. # means P,0.05 EAEASCs vs WtASCs (t-test, n = 3).
doi:10.1371/journal.pone.0085007.g004
Figure 5. Clinical scoring for disease onset and progression. The clinical scores for the HBSS-treated (n = 20), EAEASC-treated (n = 20) and
WtASC-treated (n = 20) EAE mouse groups were recorded daily for the duration of the study. WtASCs significantly reduced the clinical symptoms from
PDI13 where the EAEASCs failed to mediate any therapeutic efficacy or improvement. #means P,0.01 vs HBSS-treated EAE group (post-hoc, n = 20);N means P,0.01 vs EAEASCs-treated EAE group (post-hoc, n = 20).
doi:10.1371/journal.pone.0085007.g005
Autologous ASCs for the Treatment of EAE
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Cytokine and Chemokine expression of EAEASC
Both cell types were cultured overnight, trypsinized, and
analyzed by real-time PCR to determine the mRNA expression
levels of various cytokines and chemokines (TNFa, IL-6, MCP-1,
MIP-1a, RANTES, KC, MIP-2a and VEGF). EAEASC demon-
strated increased expression of MCP-1 and KC, and reduced
expression of VEGF (t-test, P,0.05). There is no statistical
difference between the two cell types related to their expression of
TNFa, IL-6, MIP-1a, RANTES, and MIP-2a (Fig. 4) (t-test,
P.0.05).
Therapeutic effects of EAEASC on MOG35–55 induced
chronic EAE
The therapeutic potential of EAEASCs was investigated in the
EAE model. EAEASCs and WtASCs were administrated into the
EAE mice by i.p. injection simultaneously on the day of disease
induction. Our previous work (unpublished data) demonstrated
that ASCs derived from healthy mice could significantly amelio-
rate the disease course and autoimmune mediated demyelination.
Consistent with these prior studies, infusion of WtASCs amelio-
rated the symptoms and delayed the disease progression in
comparison to the HBSS-treated controls, resulting in a statisti-
cally significant reduction of cumulative disease scores (Fig. 5).
Moreover, mice treated with WtASCs showed a delayed onset of
disease when compared with those in the HBSS-treated control
group (Fig. 5). However, animals infused with EAEASCs showed
no therapeutic improvement on the disease progression, and the
mice in this group had an earlier onset of disease than those in the
HBSS-treated control group.
Histological and immunohistochemistry analysis on the
spinal cord
Mice from the treatment and control groups were sacrificed on
PDI day 30, and the lumbar spinal cords were stained with LFB
and H&E for the assessment of demyelination and cell infiltration
respectively. Quantification of demyelination by density analysis of
LFB-stained spinal cord sections revealed a 22% decrease in
myelin density in HBSS-treated EAE mice. Furthermore,
EAEASC treatment showed no improvement in re-myelination
and had the same myelin density reduction degree (29%) as the
HBSS-treated EAE mice (Fig. 6) (post-hoc, P.0.05). In contrast,
WtASC treated animals had less demyelination, with myelin
densities similar to those mice in the normal control (post-hoc,
P.0.05). For cell infiltration analysis, as shown in Figure 6,
EAEASC treatment did not reduce the levels of cell infiltration
and had the same number of cells infiltrated (67.6613.3 cells per
field) as the HBSS-treated EAE mice (68.269.21cells per field),
while WtASC treatment (30.0610.6 cells per field) significantly
decreased the number of infiltrating cells present in the spinal
cords compared to the HBSS-treated and the EAEASC treated
mice (post-hoc, P,0.01). Immunohistochemistry staining for the
assessment of the cellular composition of the infiltrates revealed
Figure 6. Histologic and Immunohistochemical analysis on the spinal cord. Spinal cords were collected at sacrifice from 3 mice per group.
Each spinal cord was sectioned, mounted, and stained with luxol fast blue (LFB), H&E, and anti-GFAP for intact myelin, cell infiltration and astrocytes
levels. Images were acquired at 46, 406 and 106magnification. The LFB stained sections (n = 3 mice; 3 sections/mouse) were quantified for the
intensity of the blue staining using Aperio Software. The H&E stained sections (n = 3 mice; 3 sections/mouse) were quantified for the total cells per
field using Fiji/Image J software. ## means P,0.01 EAEASCs-treated vs WtASCs-treated EAE group (post-hoc, n = 9); ** means P,0.01 EAEASCs-
treated vs normal naı¨ve mouse group (post-hoc, n = 9); NNmeans P,0.01 HBSS-treated vs WtASCs-treated EAE group (post-hoc, n = 9); ¥¥ means
P,0.01 HBSS-treated vs normal naı¨ve mouse group (post-hoc, n = 9).
doi:10.1371/journal.pone.0085007.g006
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that there was increased astrocyte population in the EAEASC
treated and the HBSS-treated mice as compared to the WtASC
treated and the normal control mice (Fig. 6), Moreover, CD3,
CD11b and CD45 staining demonstrated that there were more T
cell, macrophage and B cell infiltration in the EAEASC treated
mice as compared to the WtASC treated ones (Fig. 7). As shown in
Figure 7, lesion analysis of the spinal cords also revealed that the
lesion number and size were significantly reduced in the WtASC
treated mice when compared to the EAEASC treated and the
HBSS-treated ones.
Serum cytokine levels
ELISA Assays were used to investigate the TNFa, IL-12 and IL-
17 cytokines levels in each treatment group. As illustrated in
Figure 8, WtASC treatment significantly reduced the circulating
levels of pro-inflammatory cytokines TNFa and IL-12 (post-hoc,
P,0.05) when compared to HBSS-treated EAE mice. Further-
more, the levels of TNFa and IL-12 were similar to (TNFa, post-
hoc, P.0.05) or even lower (IL-12, post-hoc, P,0.05) than those
circulating in the normal mice. However, the EAE mice treated
with EAEASC had serum TNFa and IL-12 levels indistinguish-
able from HBSS-treated EAE mice (post-hoc, P.0.05). The
circulating level of IL-17 remained the same in all the treatment
and control groups (ANOVA, P.0.05).
Discussion
Transplantation of BM-MSCs from healthy syngeneic controls
has demonstrated striking therapeutic effects and unique immuno-
modulatory capacities when delivered early to EAE mice [6,27].
ASCs have similar properties to BM-MSCs, and have received
increased attention in regenerative medicine and tissue engineer-
ing because of the abundance, easy accessibility of adipose tissues,
and the feasibility of harvest cells by a minimally invasive
procedure. Previous studies from our group [28] and other labs
[14] have showed that intraperitoneal administration of ASCs
derived from healthy mice could significantly ameliorate the
disease course and autoimmune mediated demyelination through
the regulation of the inflammatory responses. The data, showing
milder disease symptoms with decreased number of inflammatory
infiltrates and reduced demyelination, further confirmed the
immune-modulatory effects of wild type ASCs. The results
demonstrated that the therapeutic effect of WtASCs is due to
the modulation of the inflammatory response associated with the
tissue damage rather than tissue repair sustained by regeneration
of damaged neurons and oligodendrocytes. The therapeutic
benefits are related to immune suppression exerted by WtASCs
as demonstrated in other studies [6,27,28].
Figure 7. Lesion and cell infiltration analysis on the spinal cord. Spinal cords were collected at sacrifice from 3 mice per group. Each spinal
cord was sectioned, mounted, and stained with anti-CD3, CD11b, and CD45 followed by Hematoxylin counterstain for lesion size, number and cell
infiltration analysis. # means P,0.05 vs EAEASC-treated EAE group (post-hoc, n = 9); & means P,0.05 vs HBSS-treated EAE group (post-hoc, n = 9).
doi:10.1371/journal.pone.0085007.g007
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In this paper, ASCs isolated from HBSS-treated EAE mice were
cultured, analyzed in vitro, and intraperitoneally transplanted into
EAE mice in vivo to investigate whether the disease altered the
biology profiles of ASCs in vitro and the efficacy of autologous
transplantation in vivo. The EAEASCs displayed all the character-
istics that defined for MSCs in vitro. They are adherent to plastic
surfaces, fibroblast-like and spindle shaped. The EAEASCs
displayed the same characteristic surface markers. EAEASCs, like
WtASCs, are positive for surface markers CD29 and ScaI, and
negative for hematopoietic markers CD45, CD31, CD34 and
macrophage marker CD11b. The EAEASCs could readily form
single cell colonies, and differentiate into osteocytes and adipocytes
when induced under proper media. However, the results showed
that the osteogenic capacity of the EAEASCs was reduced as
compared to the WtASCs (Fig. 2). The reason that EAEASCs have
reduced osteogenic differentiation ability is unclear. There was no
difference in osteogenic markers, such as alkaline phosphatase and
runt-related transcription factor 2, in differentiated EAEASCs and
WtASCs. Assessment of their inflammatory cytokine and chemo-
kine profiles through real-time PCR demonstrated that the
EAEASCs displayed a more pro-inflammatory profile with
elevated expression of MCP-1 and KC as compared to the
WtASCs. Studies have shown that chronic inflammation adversely
affects bone formation [29,30]. The pro-inflammatory profile of
EAEASCs may play a role in their reduced differentiation capacity
along the osteogenic lineage.
Interestingly, the EAEASCs demonstrated a lack of therapeutic
efficacy when transplanted back into the EAE mice in vivo. The
data showed that the EAEASCs did not delay the disease time
course, decrease the extent of demyelination or decrease
inflammation (Fig. 5–8). It is not clear why EAEASCs lacked a
therapeutic benefit when delivered for the treatment of EAE mice.
However, when tested for in vitro cytokine and chemokine
expression levels, EAEASCs increased expression of MCP-1 in
comparison to the WtASCs. MCP-1 (known as chemokine C-C
motif ligand 2 in systematic nomenclature) is one of the key
chemokines that regulate the migration and infiltration of
monocytes/macrophages [31]. While constitutive expression of
MCP-1 in healthy CNS is relatively low, it is present and plays a
critical pathogenic role in mediating neuroinflammation in various
diseases including MS and its EAE animal model [32–34]. The
exact mechanism of MCP-1 action remains unclear, however,
numerous studies [35–39] have recognized that MCP-1 modulates
blood-brain barrier disruption and attraction of mononuclear
leukocytes migration into the CNS. In rodents with EAE, MCP-1
expression is correlated with disease severity and parallels with
disease onset [40,41]. MCP-1 synthesis inhibition by the
compound bindarit resulted in the delay, prevention and
Figure 8. Pro-inflammatory cytokine protein levels in mouse serum. Sera from 5 mice per group at sacrifice were pooled and analyzed by
ELISA to detect levels of TNF-a, IL-12, and IL-17. # means P,0.05 vs HBSS-treated EAE group (post-hoc, n = 5); N means P,0.05 vs EAEASCs-treated
EAE group (post-hoc, n = 5); & means P,0.05 vs normal naı¨ve mouse group (post-hoc, n = 5).
doi:10.1371/journal.pone.0085007.g008
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attenuation of EAE disease [34], which further supports the widely
proposed MCP-1 role in neuroinflammation. It seems that,
although they were cultured and expanded in vitro under standard
cell culture condition, the EAEASCs may have been irreversibly
altered by the diseased pro-inflammatory microenvironment in
vivo, which may contribute to the lack of EAEASC therapeutic
efficacy.
To date, clinical trials for MS have not focused on the use of
autologous cells, but have used heterologous donor cells [42,43].
Nevertheless, one study analyzed the characteristics of the BM-
MSCs from MS patients in vitro, and it concluded that BM-MSCs
from individuals with MS, compared to individuals without MS,
displayed a normal phenotype and were similar in proliferation, in
vitro differentiation potential and cell surface antigen expression
[44]. Four Phase 1 clinical trials for the treatment of MS using
autologous BM-MSCs have been approved [45–49]. The prelim-
inary data from these trials demonstrated promising data in terms
of clinical parameters and immunological analysis [46]. However,
the early findings will require further validation with larger studies
due to the limited number of the patients enrolled in the trials and
the uncontrolled natures of the trials.
In conclusion, the ASCs from mice with EAE displayed a
normal phenotype, typical MSC surface antigen expression, and in
vitro osteogenic and adipogenic differentiation capacity; however,
the degrees of osteogenesis and CFU formation were compromised
relative to WtASC. Most importantly, the EAEASCs lost their
therapeutic efficacy for the treatment of EAE mice in vivo, which
may be due to the distinct pro-inflammatory secretory profile they
developed in the setting of chronic neuroinflammation. Thus,
autologous transplantation of ASCs for the treatment of the mouse
model of EAE appears to lacking efficacy. While careful validation
and experimental testing must be performed before any extrap-
olation is made based on the animal studies, the current work
suggests that autologous ASCs from individuals with MS should be
evaluated and compared extensively to allogeneic ASCs from
healthy individuals prior to clinical trials.
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